Baseline characteristics and prior lines of therapies of TCR patients studied
| . | All patients (N = 73) . | CAR-Ts (n = 36) . | BiAbs∗ (n = 37) . | P value . |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age, y, median (range) | 62 (36-82) | 59 (36-76) | 64 (42-82) | NS |
| ≥70, n (%) | 17 (23.3) | 4 (11.1) | 13 (35.1) | .015 |
| Male, n (%) | 44 (60.3) | 20 (55.6) | 24 (64.9) | NS |
| ECOG PS, 0-1, n (%) | 61 (83.6) | 32 (88.9) | 29 (78.4) | NS |
| EMD, n (%) | 24 (33.8) | 7 (19.4) | 17 (48.6) | .009 |
| High-risk cytogenetic†, n (%) | 24 (33.3) | 12 (33.3) | 12 (33.3) | NS |
| ISS 3, n (%) | 15 (23.1) | 8 (22.2) | 7 (24.1) | NS |
| R-ISS 3, n (%) | 11 (16.9) | 6 (16.7) | 5 (17.2) | NS |
| Prior LOT | ||||
| Prior lines, median (range) | 3 (2-7) | 3 (2-6) | 4 (2-7) | .003 |
| >3, n (%) | 36 (49.3) | 11 (30.5) | 25 (67.6) | .002 |
| Exposed to PIs V/K/Ixa, % | 100/65.8/5.5 | 100/63.8/5.6 | 100/67.6/5.4 | NS |
| Refractory to PIs V/K/Ixa, % | 67.1/56.2/5.5 | 69.4/47.2/5.6 | 64.9/64.9/5.4 | NS |
| Exposed to IMiDs T/R/P, % | 52.1/100.0/72.6 | 52.8/100.0/75.0 | 51.4/100.0/70.3 | NS |
| Refractory to IMiDs T/R/P, % | 13.7/94.5/68.5 | 13.9/97.2/66.7 | 13.5/91.9/70.3 | NS |
| Exposed to anti-CD38 moAbs; D/Isa, % | 98.6/2.7 | 97.2/5.6 | 100.0/0 | NS |
| Refractory to anti-CD38 moAbs; D/Isa, % | 98.6/2.7 | 97.2/5.6 | 100.0/0 | NS |
| Belantamab mafadotin, n (%) | 4 (5.5) | 1 (2.8) | 3 (8.1) | NS |
| Penta-class exposed, n (%) | 45 (61.6) | 22 (61.1) | 23 (62.2) | NS |
| Penta-class refractory, n (%) | 17 (23.3) | 6 (16.7) | 11 (29.7) | NS |
| ASCT, n (%) | 60 (88.2) | 32 (88.9) | 28 (75.7) | NS |
| Allo-SCT, n (%) | 2 (2.7) | 1 (2.8) | 1 (2.7) | NS |
| . | All patients (N = 73) . | CAR-Ts (n = 36) . | BiAbs∗ (n = 37) . | P value . |
|---|---|---|---|---|
| Baseline characteristics | ||||
| Age, y, median (range) | 62 (36-82) | 59 (36-76) | 64 (42-82) | NS |
| ≥70, n (%) | 17 (23.3) | 4 (11.1) | 13 (35.1) | .015 |
| Male, n (%) | 44 (60.3) | 20 (55.6) | 24 (64.9) | NS |
| ECOG PS, 0-1, n (%) | 61 (83.6) | 32 (88.9) | 29 (78.4) | NS |
| EMD, n (%) | 24 (33.8) | 7 (19.4) | 17 (48.6) | .009 |
| High-risk cytogenetic†, n (%) | 24 (33.3) | 12 (33.3) | 12 (33.3) | NS |
| ISS 3, n (%) | 15 (23.1) | 8 (22.2) | 7 (24.1) | NS |
| R-ISS 3, n (%) | 11 (16.9) | 6 (16.7) | 5 (17.2) | NS |
| Prior LOT | ||||
| Prior lines, median (range) | 3 (2-7) | 3 (2-6) | 4 (2-7) | .003 |
| >3, n (%) | 36 (49.3) | 11 (30.5) | 25 (67.6) | .002 |
| Exposed to PIs V/K/Ixa, % | 100/65.8/5.5 | 100/63.8/5.6 | 100/67.6/5.4 | NS |
| Refractory to PIs V/K/Ixa, % | 67.1/56.2/5.5 | 69.4/47.2/5.6 | 64.9/64.9/5.4 | NS |
| Exposed to IMiDs T/R/P, % | 52.1/100.0/72.6 | 52.8/100.0/75.0 | 51.4/100.0/70.3 | NS |
| Refractory to IMiDs T/R/P, % | 13.7/94.5/68.5 | 13.9/97.2/66.7 | 13.5/91.9/70.3 | NS |
| Exposed to anti-CD38 moAbs; D/Isa, % | 98.6/2.7 | 97.2/5.6 | 100.0/0 | NS |
| Refractory to anti-CD38 moAbs; D/Isa, % | 98.6/2.7 | 97.2/5.6 | 100.0/0 | NS |
| Belantamab mafadotin, n (%) | 4 (5.5) | 1 (2.8) | 3 (8.1) | NS |
| Penta-class exposed, n (%) | 45 (61.6) | 22 (61.1) | 23 (62.2) | NS |
| Penta-class refractory, n (%) | 17 (23.3) | 6 (16.7) | 11 (29.7) | NS |
| ASCT, n (%) | 60 (88.2) | 32 (88.9) | 28 (75.7) | NS |
| Allo-SCT, n (%) | 2 (2.7) | 1 (2.8) | 1 (2.7) | NS |
Allo-SCT, allogeneic stem cell transplantation; ASCT, autologous stem cell transplantation; D, daratumumab; ECOG, Eastern Cooperative Oncology Group; Isa, isatuximab; ISS, International Staging System; Ixa, ixazomib; K, carfilzomib; NS, not significant; P, pomalidomide; PS, performance status; R, lenalidomide; R-ISS, Revised International Staging System; T, thalidomide; V, bortezomib.
Missing data in the BiAbs group: extramedullary evaluation for 2 patients; fluorescence in situ hybridization for 1 patient; and ISS and R-ISS for 8 patients.
t(4;14), t(14;16), and del17p.